Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4- methylenedioxymethamphetamine in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 136-145

  Mas, Marta ^a   Farré, Magí ^a   De la Torre, Rafael ^a   Roset, Pere N ^a   Ortuño, Jordi ^a   Segura, Jordi ^a   Camí, Jordi ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; PLACEBO; SEDATIVE AGENT;

ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFECT; DRUG HALF LIFE; DRUG SCREENING; HEART RATE; HUMAN; MALE; MYDRIASIS; NEUROENDOCRINOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; AREA UNDER CURVE; BODY TEMPERATURE; CARDIOVASCULAR SYSTEM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALLUCINOGENS; HEMODYNAMIC PROCESSES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROSECRETORY SYSTEMS; PROLACTIN; PUPIL;

EID: 0032968382     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Anderson IM, Cowen PJ and Grahame-Smith DG (1990) The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 100: 498-503.
2. R Analyzer. Clin Chem 37:291.
3. Brauer L, Ambre J and de Wit H (1996) Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. J Clin Psychopharmacol 16:72-76.
4. Camí J and Farré M (1996) Éxtasis, la droga de la ruta del bacalao Med Clin (Barc) 106:711-716.
5. Camí J, Mas M, Farré M, San L, Roset PN, Mas A, Poudevida S and de la Torre R (1998) Pharmacological effects of MDMA in humans: Dose-finding pilot study, in Problems of Drug Dependence (Harris LS ed) p 290, Nat Inst Drug Abuse Res Mon 178, Washington DC: Supt of Doc, US Govt Prin Off, DHHS (NIH 98-4305).
6. Costong GM, van Oers RJ, Leerkes B and Janson PC (1995) Evaluation of the DPC immulite random access immunoassay analyser. Eur J Clin Chem Clin Biochem 33:887-892.
7. Davis WM, Hatoum HT and Waters IW (1987) Toxicity of MDA (3,4-methylenedioxy-amphetamine) considered for relevance to hazards of MDMA (ecstasy) abuse. Alcohol Drug Res 7:123-124.
8. De la Torre K, Ortuño J, Mas M, Farré M and Segura J (1999) Fatal MDMA intoxication. Lancet 353:593.
9. De Wit H, Clark M and Brauer LH (1997) Effects of d-amphetamine in grouped versus isolated humans. Pharmacol Biochem Behav 57:333-340.
10. Demirkiran M, Jankovic J and Dean JM (1996) Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 19:157-164.
11. Dommisse CS, Schulz SC, Narasimhachari N, Blackard WG and Hamer RM (1984) The neuroendocrine and behavioral response to dextroamphetamine in normal individuals. Biol Psychiatry 19:1305-1315.
12. Dowling GP, McDnough ET and Best R (1987) "Eve and Ecstasy" (1987): A report of five deaths associated with the use of MDEA and MDMA. JAMA 267:1615-1617.
13. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18:335-340.
14. Gouzoulis E, von Bardeleben U, Rupp A, Kovar K and Hermle L (1993) Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology 8:187-193.
15. Green AR and Goodwin GM (1996) Ecstasy and neurodegeneration. Br Med J 312:1493-1494.
16. Grob CS, Poland RE, Chang L and Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behav Brain Res 73:103-107.
17. Helmlin HJ, Bracher K, Bourquin D, Bonlanthen D and Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamme (MDMA) and its metabolites in plasma and orine by HPLC-DAD and GC-MS. J Anal Toxicol 20:432-440.
18. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA and Forsling M (1998) Low-dose MDMA ("ecstasy") induces vasopresin secretion. Lancet 351:1784.
19. Henry JA, Jeffreys KJ and Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387.
20. Jasinski DR and Preston KL (1986) Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. Drug Alcohol Depend 17:1-13.
21. Jenkins AJ and Cone EJ, (1998) Pharmacokinetics: Drug absorption, distribution and elimination, in Drug Abuse Handbook (Karch SB ed) pp 151-201, CRC Press, Boca Raton, FL.
22. Kobayashi Y, Amitani K, Watanabe F and Miyai K (1979) Fluorescence polarization immunoassay for cortisol. Clin Chim Acta 92:241-247.
23. Martin WR, Sloan JW, Sapira JD and Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258.
24. McCann U, Ridenour A, Shaham Y and Ricaurte GA (1994) Serotonin neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): A controlled study in humans. Neuropsychopharmacology 10:129-138.
25. McCann U, Slate SO and Ricaurte GA (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Drug Safety 15:107-115.
26. McCann UD, Szabo Z, Scheffel U, Dannals RF and Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
27. Meltzer HY and Maes M (1994) Effects of buspirone on plasma prolactin and cortisol levels in major depressed normal subjects. Biol Psychiatry 35:316-323.
28. Mendelson J, Jones RT, Upton R and Peyton J (1995) Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 57:559-568.
29. Nash JF Jr, Meltzer HY and Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245:873-879.
30. Nurnberger JI Jr, Simmons-Alling S, Kessler L, Jimerson S, Schreiber J, Hollander E, Tamminga CA, Nadi NS, Goldstein DS and Gershon ES (1984) Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man. Psychopharmacology 84:200-204.
31. Pickworth WB, Fant RV and Bunker EB (1998) Effects of abused drugs on pupillary size and the light reflex, in Drug Abuse Handbook (Karch SB, ed) pp 266-275, CRC Press, Boca Raton, FL.
32. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I and Langston JW (1988) 5-Hydroxy-indoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 474:359-363.
33. 1c/2 receptors. Endocrinology 133:661-667.
34. Schmid B, Bircher J, Preisig R and Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative o-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624.
35. Shumaker RC (1986) A basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 17:331-348.
36. Sommers De K, van Wyk M and Snyman JR (1994) Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Eur J Clin Pharmacol 46:441-444.
37. Steele TD, McCann UD and Ricaurte GA (1994) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): Pharmacology and toxicology in animals and humans. Addiction 89:539-551.
38. Verebey K, Alrazi J and Jaffe JH (1988) The complications of "ecstasy" (MDMA). JAMA 269:1649-1650.
39. Vollenweider FX, Gamma A, Liechti M and Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19:241-251.
40. White SR, Obradovic T, Imel KM and Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455-479.
41. Yatham LN (1996) Prolactin and cortisol responses to fenfluramine challenge in mania. Biol Psychiatry 39:285-288.